IPP Bureau
Solara Active Pharma approves rights issue of Rs. 450 Cr
By IPP Bureau - July 05, 2023
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
BDR Pharma's Nilotinib sets a new standard in the treatment of Philadelphia Chromosome-positive leukaemia
By IPP Bureau - July 05, 2023
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
Biocon Biologics' Hulio Biosimilar to Humira now available in the US
By IPP Bureau - July 04, 2023
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Lupin receives approval from FDA for Cyanocobalamin Nasal Spray
By IPP Bureau - July 04, 2023
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
Adare Pharma divests Adare Biome to dsm-firmenich
By IPP Bureau - July 04, 2023
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
SHL Medical acquires 100% of the shares in LCA Automation
By IPP Bureau - July 04, 2023
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
By IPP Bureau - July 04, 2023
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24
By IPP Bureau - July 03, 2023
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Granules India successfully completes Two US FDA Audits in a span of 2 weeks
By IPP Bureau - July 03, 2023
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Annovis’ Buntanetap in PD faces complex road ahead despite phase III progress, says GlobalData
By IPP Bureau - July 03, 2023
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
By IPP Bureau - July 03, 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
VitaDAO launches VITA-FAST tokens, revolutionizing governance in longevity research
By IPP Bureau - July 03, 2023
The VITA-FAST tokens have been met with overwhelming interest
Merck to expand reagent production capacity in China
By IPP Bureau - June 30, 2023
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
ENPICOM secures extended financing from current investors
By IPP Bureau - June 30, 2023
Investment will help fuel international partnerships, grow IGX Platform functionality, and diversify proposition with new generative AI solutions
Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
By IPP Bureau - June 30, 2023
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
